Dynamics of malaria-specific antibody immune responses in a setting implementing seasonal malaria chemoprevention in Uganda

Authors: Jane Achan, Stephen Tukwasibwe, Richard Kajubi, Asadu Sserwanga, Godfrey Magumba, Anthony Nuwa, Jimmy Opigo, Isaac Sewanyana, James K Tibenderana, Prasanna Jagannathan

Seasonal malaria chemoprevention (SMC) reduces malaria exposure, leading to lower antibody responses over time. Robust exit strategies are essential when discontinuing SMC to prevent potential rebound effects.

Seasonal malaria chemoprevention (SMC) using sulfadoxine-pyrimethamine and amodiaquine (SPAQ) has significantly reduced malaria-associated morbidity and mortality across settings. However, data on the impact of SMC on host immunity is limited. To understand the dynamics of malaria specific antibody immune responses in settings implementing SMC, we comprehensively profiled antibody immune responses in children aged three months to 15 years before and after single and multiple rounds of SMC in Karamoja subregion, northeastern Uganda.

This poster was presented at the 2025 Annual Meeting of the American Society of Tropical Medicine and Hygiene, held on 9-13 November in Toronto, Canada.